REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA

Clinical trials for REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA trials appear

Sign up with your email to follow new studies for REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New Triple-Threat attack on aggressive blood cancer

Disease control Not yet recruiting

This study is testing whether combining three existing drugs—ruxolitinib, cladribine, and venetoclax—can help control a rare and aggressive form of T-cell leukemia that has returned or not responded to prior treatment. The main goals are to see if the combination is safe and if i…

Matched conditions: REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA

Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA

Get alerted when new REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA trials appear

New Triple-Threat attack on aggressive blood cancer